Related references
Note: Only part of the references are listed.Structural Models for Interactions between the 20S Proteasome and Its PAN/19S Activators
Beth M. Stadtmueller et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
A Novel Domain Mediates Insulin-Induced Proteasomal Degradation of Insulin Receptor Substrate 1 (IRS-1)
Sigalit Boura-Halfon et al.
MOLECULAR ENDOCRINOLOGY (2010)
Structure, Assembly and Homeostatic Regulation of the 26S Proteasome
Youming Xie
JOURNAL OF MOLECULAR CELL BIOLOGY (2010)
Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells
Haiming Xu et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Multiple Forms of Proteasomes and their Role in Tumor Fate
Natalia Sharova et al.
RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY (2008)
Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2
Ioannis A. Voutsadakis
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2007)
Genetic and expression aberrations of E3 ubiquitin ligases in human breast cancer
Ceshi Chen et al.
MOLECULAR CANCER RESEARCH (2006)
Proteasome inhibitors induce death but activate NF-κB on endometrial carcinoma cell lines and primary culture explants
Xavier Dolcet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Degradation of insulin-like growth factor-1 receptor occurs via ubiquitin-proteasome pathway in human lung cancer cells
Stephana Carelli et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Exclusion of immune proteasomes from mouse ascitic carcinoma Krebs-II cells
T. M. Astakhova et al.
BIOLOGY BULLETIN (2006)
Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue
L Chen et al.
CANCER RESEARCH (2005)
The proteasome: a novel target for cancer chemotherapy
JB Almond et al.
LEUKEMIA (2002)
Share Paper
